当期报告
Onconetix(ONCO)04-09 04:15
$Onconetix(ONCO)$ 8-K Current report, item 8.01 Accession Number: 0001213900-24-031167 Act: 34 Size: 200 KB 网页链接
简介:Onconetix, Inc.于2018年10月26日在特拉华州注册成立。该公司是一家商业阶段的生物技术公司,专注于为临床医生和患者提供肿瘤学专有疗法、诊断和服务的研究、开发和商业化。该公司目前拥有FDA批准的用于治疗良性前列腺增生(BPH)(一种前列腺疾病)的口服治疗药物EntadFi,以及用于在前列腺癌肿瘤学中筛查和诊断前列腺特异性抗原(PSA)评估不确定的男性的先进专有诊断系统Proclarix。
今开:0.156 | 昨收:0.1589 |
最高:0.156 | 最低:0.13 |
涨停价: | 跌停价: |
总市值:2980748 |
Onconetix(ONCO)04-09 04:15
$Onconetix(ONCO)$ 8-K Current report, item 8.01 Accession Number: 0001213900-24-031167 Act: 34 Size: 200 KB 网页链接
Onconetix(ONCO)05-14 04:55
$Onconetix(ONCO)$ 8-K Current report, items 3.01 and 9.01 Accession Number: 0001213900-24-042369 Act: 34 Size: 203 KB 网页链接
Onconetix(ONCO)05-16 04:15
$Onconetix(ONCO)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001213900-24-043580 Act: 34 Size: 26 KB 网页链接
Onconetix(ONCO)04-02 04:15
$Onconetix(ONCO)$ NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Accession Number: 0001213900-24-028725 Act: 34 Size: 25 KB 网页链接
Onconetix(ONCO)03-14 05:05
$Onconetix(ONCO)$ 8-K/A [Amend] Current report, item 9.01 Accession Number: 0001213900-24-022215 Act: 34 Size: 220 KB 网页链接
Onconetix(ONCO)04-12 04:45
$Onconetix(ONCO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001213900-24-032225 Act: 34 Size: 13 MB 网页链接
Onconetix(ONCO)04-27 05:35
$Onconetix(ONCO)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001213900-24-036738 Act: 33 Size: 28 MB 网页链接
Onconetix(ONCO)02-22 05:15
$Onconetix(ONCO)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001213900-24-015752 Size: 5 KB 网页链接
Onconetix(ONCO)02-28 05:35
$Onconetix(ONCO)$ 8-K/A [Amend] Current report, items 2.01, 8.01, and 9.01 Accession Number: 0001213900-24-017544 Act: 34 Size: 982 KB 网页链接
Onconetix(ONCO)04-27 04:25
$Onconetix(ONCO)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001213900-24-036645 Act: 34 Size: 288 KB 网页链接
亿欧网05-09 15:10
首尔,2024年5月8日 —— 韩国创新生物技术研发商Avelos Therapeutics(简称:Avelos)今日宣布完成B轮融资。此轮融资将助力公司推进其精准医疗服务平台,专注于开发针对癌症细胞的onco-therapeutics。Avelos的疗法基于特定的生物标志物,旨在为癌症患者提供个体化的治疗方案。
Avelos Therape...查看全文
$Onconetix(ONCO)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001213900-24-045172 Act: 34 Size: 7 MB 网页链接
$Onconetix(ONCO)$ NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB Accession Number: 0001213900-24-043580 Act: 34 Size: 26 KB 网页链接
$Onconetix(ONCO)$ 8-K Current report, items 3.01 and 9.01 Accession Number: 0001213900-24-042369 Act: 34 Size: 203 KB 网页链接
$Onconetix(ONCO)$ S-1/A [Amend] General form for registration of securities under the Securities Act of 1933 Accession Number: 0001213900-24-036738 Act: 33 Size: 28 MB 网页链接
$Onconetix(ONCO)$ 8-K Current report, items 1.01, 8.01, and 9.01 Accession Number: 0001213900-24-036645 Act: 34 Size: 288 KB 网页链接
$Onconetix(ONCO)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001213900-24-032225 Act: 34 Size: 13 MB 网页链接
$Onconetix(ONCO)$ 8-K Current report, item 8.01 Accession Number: 0001213900-24-031167 Act: 34 Size: 200 KB 网页链接
$Onconetix(ONCO)$ NT 10-K Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 Accession Number: 0001213900-24-028725 Act: 34 Size: 25 KB 网页链接
$Onconetix(ONCO)$ 8-K/A [Amend] Current report, item 9.01 Accession Number: 0001213900-24-022215 Act: 34 Size: 220 KB 网页链接
$Onconetix(ONCO)$ 8-K/A [Amend] Current report, items 2.01, 8.01, and 9.01 Accession Number: 0001213900-24-017544 Act: 34 Size: 982 KB 网页链接